CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health

CD&R and McKesson agreed to acquire Option Care Health for $32.05 per share, representing an approximately $5.8 billion total enterprise value. The article excerpt does not provide a premium, financing details, or expected closing date.

Analysis

The strategic value to McKesson is less the headline transaction size than access to a larger home/alternate-site infusion platform: if the arrangement enables tighter coordination of specialty distribution and care delivery, it could help McKesson participate in the shift away from higher-cost sites and defend relevance as therapies become more complex. The counterweight is channel neutrality—other providers or suppliers could view McKesson differently if it has an ownership interest in a competing infusion operator. CD&R’s participation may share capital and execution risk, but also means McKesson may not capture all operating upside. Competitors such as CVS Coram, Soleo Health and Amerita could face stronger scale competition, though the deal alone does not establish a near-term market-share shift.

Near term, OPCH is principally a transaction-spread and closing-risk situation, not an operating rerating: the stated $32.05 per share is a conditional value, and the excerpt does not provide consideration details, financing, approvals, timing or termination protections. Over 1–3 months, verify the full agreement and regulatory path. Over 6–18 months, the thesis depends on integration, referral economics and whether McKesson can grow the platform without alienating commercial counterparties. The contrarian risk is treating strategic fit as assured synergy; deal structure and customer response may limit value capture. No valuation conclusion is possible without OPCH’s current price and complete terms.

Key Decisions for Investors

• OPCH: Treat as a deal-arbitrage watch, not an unconditional long. Compare the live share price with $32.05 only after confirming the full consideration, expected close date, financing and termination conditions; require a spread that compensates for time and break risk.
• MCK: Avoid paying up on strategic-fit headlines. Reassess after disclosure of McKesson’s ownership share, funding, governance and expected economics; monitor commentary from providers and suppliers for signs of channel-neutrality concerns.
• Catalyst/risk checklist: Track regulatory review, shareholder and financing conditions, and any revised closing timetable. A material delay, adverse approval condition or termination would falsify the OPCH convergence thesis.
• Competitor watch: Monitor CVS Coram, Soleo Health and Amerita for evidence of contracting, capacity or referral shifts; absent such evidence, do not infer immediate share loss from the acquisition announcement.